Zurich Insurance Group Ltd FI Boosts Holdings in Exelon Co. (NYSE:EXC)

Share on StockTwits

Zurich Insurance Group Ltd FI raised its holdings in shares of Exelon Co. (NYSE:EXC) by 41.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 330,964 shares of the energy giant’s stock after acquiring an additional 96,410 shares during the quarter. Zurich Insurance Group Ltd FI’s holdings in Exelon were worth $15,866,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. Rockefeller Capital Management L.P. boosted its stake in shares of Exelon by 3,771.2% during the 1st quarter. Rockefeller Capital Management L.P. now owns 30,195 shares of the energy giant’s stock worth $1,514,000 after purchasing an additional 29,415 shares during the last quarter. First National Bank & Trust Co. of Newtown boosted its stake in shares of Exelon by 7.9% during the 2nd quarter. First National Bank & Trust Co. of Newtown now owns 11,890 shares of the energy giant’s stock worth $570,000 after purchasing an additional 870 shares during the last quarter. Capital Investment Advisors LLC acquired a new stake in shares of Exelon during the 2nd quarter worth about $247,000. USS Investment Management Ltd boosted its stake in shares of Exelon by 247.6% during the 1st quarter. USS Investment Management Ltd now owns 878,381 shares of the energy giant’s stock worth $44,020,000 after purchasing an additional 625,681 shares during the last quarter. Finally, Boston Private Wealth LLC boosted its stake in shares of Exelon by 12.4% during the 2nd quarter. Boston Private Wealth LLC now owns 4,799 shares of the energy giant’s stock worth $230,000 after purchasing an additional 530 shares during the last quarter. Hedge funds and other institutional investors own 79.00% of the company’s stock.

Several research firms have issued reports on EXC. ValuEngine cut shares of Exelon from a “buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Barclays raised shares of Exelon from an “equal weight” rating to an “overweight” rating and decreased their target price for the stock from $54.00 to $52.00 in a research report on Tuesday, August 13th. They noted that the move was a valuation call. UBS Group raised their target price on shares of Exelon from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, September 6th. SunTrust Banks set a $49.00 target price on shares of Exelon and gave the stock a “hold” rating in a research report on Tuesday, September 3rd. Finally, Morgan Stanley raised shares of Exelon from an “equal weight” rating to an “overweight” rating in a research report on Friday, September 6th. Six investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $50.97.

In other news, CEO Calvin Butler, Jr. sold 31,000 shares of Exelon stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $47.59, for a total transaction of $1,475,290.00. Following the sale, the chief executive officer now owns 40,331 shares in the company, valued at $1,919,352.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.27% of the company’s stock.

NYSE EXC traded up $0.64 during mid-day trading on Friday, hitting $48.44. The company’s stock had a trading volume of 4,336,981 shares, compared to its average volume of 5,383,967. Exelon Co. has a 52-week low of $42.19 and a 52-week high of $51.18. The stock’s fifty day simple moving average is $46.23 and its two-hundred day simple moving average is $48.44. The company has a debt-to-equity ratio of 0.95, a current ratio of 0.90 and a quick ratio of 0.77. The firm has a market capitalization of $45.95 billion, a P/E ratio of 15.52, a price-to-earnings-growth ratio of 4.40 and a beta of 0.26.

Exelon (NYSE:EXC) last posted its quarterly earnings results on Thursday, August 1st. The energy giant reported $0.60 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.03). Exelon had a net margin of 6.43% and a return on equity of 8.47%. The business had revenue of $7.69 billion during the quarter, compared to analysts’ expectations of $7.03 billion. During the same quarter in the previous year, the business posted $0.71 EPS. The company’s quarterly revenue was down 4.8% on a year-over-year basis. On average, equities analysts forecast that Exelon Co. will post 3.14 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were paid a dividend of $0.363 per share. The ex-dividend date was Wednesday, August 14th. This represents a $1.45 dividend on an annualized basis and a dividend yield of 3.00%. Exelon’s dividend payout ratio is currently 46.47%.

Exelon Company Profile

Exelon Corporation, a utility services holding company, engages in energy generation and delivery businesses in the United States and Canada. It owns nuclear, fossil, wind, hydroelectric, and solar generating facilities. The company also sells electricity to wholesale and retail customers; and sells natural gas, renewable energy, and other energy-related products and services.

Further Reading: Options Trading – What is a Straddle?

Want to see what other hedge funds are holding EXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelon Co. (NYSE:EXC).

Institutional Ownership by Quarter for Exelon (NYSE:EXC)

Receive News & Ratings for Exelon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelon and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.